The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1539
January 29, 2018
View Complete Issue         Table of Contents 2019 
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes
January 29, 2018 (Issue: 1539)
The FDA has approved semaglutide (Ozempic – Novo Nordisk), a long-acting injectable GLP-1 (glucagon-like peptide-1) receptor agonist, for once-weekly treatment of adults with type 2 diabetes. It is the sixth GLP-1 receptor agonist to be...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes
Article code: 1539b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.